Clinical Research Directory

Inclusion Criteria: * Histologically confirmed with advanced breast cancer. * Eastern Cooperative Oncology Group (ECOG) performance status was 0 - 2. * Hemoglobin≥10.0g/dL, Neutrophil count≥1.5×10\^9/L, Platelet count≥75×10\^9/L; total bilirubin(TBIL)≤1.5×ULN; alkaline phosphatase(AKP), aspartate aminotransferase(AST),ALT≤2.5×ULN(without metastasis of the liver), AKP,AST,ALT≤5×ULN(with metastasis of the liver); BUN≤1.5×ULN, Cr≤1.5×ULN. * Patient received 1-2 kinds of cytotoxic chemotherapy previously. * Patient never received capecitabine or other oral fluorouracil. Exclusion Criteria: * Patients who are suffering from serious organ dysfunction. * HIV positive or other immunodeficiency disease. * Patients who had used long time or are using immunosuppressant drugs. * Patients who had active infection. * Patients who were allergic to fluorouracil. * Pregnant or lactating women. * History of other malignancies. * Other situations that the researchers considered unsuitable for this study.